(11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall ...
Palvella Therapeutics reports Phase 2 data showing 73% improvement with QTORIN rapamycin gel in cutaneous venous ...
CEL-SCI Corporation (NYSE:CVM) reported first quarter fiscal year 2023 results on February 15, 2023 and filed its Form 10-Q with the SEC. The company has continued to compile the clinical ...
CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy. 9 Out of the Last 10 Summers this ...
Researchers at the Cornell University College of Veterinary Medicine (CVM) are a step closer to finding the fountain of youth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback